REPL DEADLINE: Levi & Korsinsky Reminds Replimune Group, Inc. Investors of Upcoming Securities Class Action Deadline

Alert: Replimune shares collapsed from a $10.73 Class Period high to $1.70 following the FDA's rejection of the RP1 biologics license application, a cumulative decline of roughly 84% that the complaint alleges followed disclosures correcting earlier statements about the resubmission.

NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP alerts investors in Replimune Group, Inc. (NASDAQ: REPL) of a pending securities class action filed on behalf of shareholders who purchased securities between October 20, 2025 and April 10, 2026. Find out if you may qualify to recover losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

REPL closed at a Class Period high of $10.73 on December 8, 2025. On April 10, 2026, shares fell $1.15, or 19.46%, to $4.76 before trading was halted. On the next trading day, April 13, 2026, shares fell another $3.06, or 64.29%, to close at $1.70 — a cumulative decline of approximately $9.03 per share, or 84.16%, from the Class Period high. Investors have until October 5, 2026 to seek lead plaintiff status.

The Two-Day Market Repricing of REPL

Both trading sessions occurred on unusually heavy volume, according to the filing. The first leg followed the FDA's publication, during market hours, of a Complete Response Letter rejecting the biologics license application for RP1 in combination with nivolumab. The second leg followed an after-market press release the same day in which the Company acknowledged that the FDA had preferred a randomized controlled trial.

What the Market Reaction Reflected, as Alleged

As set forth in the complaint, the FDA stated that its study design concerns had been "clearly communicated" in multiple interactions and that those concerns "were not addressed." The agency also stated that the resubmission relied on data from an early unplanned analysis representing 10% of planned enrollment, and that this data was "insufficient to support an efficacy claim." It is alleged that shareholders purchased at prices that did not reflect these conditions.

Alleged Investor Harm by the Numbers

• Class Period high closing price: $10.73 per share on December 8, 2025
• April 10, 2026 decline: $1.15 per share, or 19.46%, to $4.76
• April 13, 2026 decline: $3.06 per share, or 64.29%, to $1.70
• Cumulative decline from Class Period high: approximately $9.03 per share, or 84.16%
• Both decline sessions occurred on unusually heavy trading volume
• Class Period: October 20, 2025 through April 10, 2026

"A stock that loses more than 80% of its value across two heavily traded sessions raises the question of what shareholders were told before that repricing occurred. The complaint alleges investors purchased REPL without material information about how the FDA viewed the underlying trial data." -- Joseph E. Levi, Esq.

Submit your information here or call (212) 363-7500.

ABOUT THE FIRM — For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years. Investors who suffered losses have until October 5, 2026 to seek appointment as lead plaintiff.

Frequently Asked Questions About the REPL Lawsuit

Q: How much did REPL stock drop? A: Shares fell approximately 84.16% cumulatively from the Class Period high, a decline of about $9.03 per share, after the Company disclosed the FDA's Complete Response Letter rejecting the RP1 biologics license application. Investors who purchased shares during the Class Period at artificially inflated prices and suffered losses may be eligible to seek compensation.

Q: When did Replimune Group, Inc. allegedly mislead investors? A: The Class Period runs from October 20, 2025 to April 10, 2026. The complaint alleges that corrective disclosures revealed information that caused a significant stock decline.

Q: What court was the REPL class action filed in? A: The case was filed in the United States District Court for the District of Massachusetts, governed by the Private Securities Litigation Reform Act of 1995.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I already sold my REPL shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.

Q: What if Replimune Group, Inc. goes bankrupt before the case resolves? A: Securities class action claims may survive bankruptcy in many circumstances. D&O insurance policies are frequently a potential source of settlement funds.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.